Meeting
2018 ASCO Annual Meeting
A large, multicenter, retrospective study to identify a cutoff of MGMT methylation status by quantitative pyrosequencing approach in patients (PTS) with glioblastoma (GBM).
Authors
Giuseppe Lombardi
Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
Giuseppe Lombardi , Luisa Bellu , Veronica Villani , Simona Rizzato , Marco Russo , Mariantonia Carosi , Elisa De Carlo , Lorena Biasini , Marina Paola Gardiman , Pasquale Fiduccia , Ardi Pambuku , Alessandro Della Puppa , Miran Skrap , Franco Servadei , Domenico D'Avella , Carmine Maria Carapella , Mario Caccese , Roberta Bertorelle , Andrea Pace , Vittorina Zagonel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2012)
DOI
10.1200/JCO.2018.36.15_suppl.2012
Abstract #
2012
Poster Bd #
170
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Treatment patterns of patients with glioblastoma multiforme in the real-world setting in a developing country.
First Author: Juan José Sánchez Hernández
Poster
2022 ASCO Annual Meeting
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
First Author: Julia Katharina Schwarze
Poster
2019 ASCO Annual Meeting
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
First Author: Patrick Roth
Poster
2016 ASCO Annual Meeting
A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.
First Author: John H. Sampson